• English
    X

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    Maryland Department of Health
    Newsroom

    ​​

    INVESTIGATION OF POSSIBLE CONNECTION BETWEEN MENINGITIS AND EPIDURAL STEROID

    ​

    BALTIMORE (October 3, 2012) – The Maryland Department of Health and Mental Hygiene (DHMH) is investigating an association between spinal injections and the development of meningitis as part of a larger multi-state investigation. At this time, DHMH has identified two cases among Maryland residents, one whom has died. No case information will be released.

    This situation was first identified when a cluster of patients in a Tennessee ambulatory care clinic developed meningitis or stroke symptoms within 1 month of receiving an epidural spinal injection with a steroid. Aspergillus meningitis was identified in one of these patients; no organism has been identified in the others. North Carolina has also identified a possible association between the injection of this product and the development of meningitis, and investigations for additional cases are underway in multiple other states.​

    Although the source of these illnesses is not yet known, methylprednisolone acetate (Solumedrol) from a single manufacturer was used for all of the affected patients, and the company has voluntarily recalled this product.​

    Maryland DHMH has contacted all the facilities where implicated lots of this product were distributed to ensure removal of the product and to facilitate notification of patients potentially exposed from July 30 to September 28, 2012.​

    Facilities that have received and pulled from use the affected product are:

    Berlin Interventional Pain Management, Berlin, MD

    Box Hill Surgery Center, Abingdon, MD

    Greenspring Surgery Center, Baltimore, MD

    Harford County Ambulatory Surgery Center, Edgewood, MD

    Maryland Pain Specialists, Towson, MD

    SurgCenter of Bel Air, Bel Air, MD Zion Ambulatory Center, Baltimore, MD​

    Symptoms of meningitis can include but are not limited to fever, headache, neck stiffness, photophobia, nausea, or vomiting. Stroke symptoms can include but are not limited to double vision, slurred speech, weakness on one side of the body, or difficulty walking. Patients who have received a spinal injection at one of these facilities from July 30 to September 28, 2012 and are experiencing new symptoms consistent with meningitis or stroke should contact their healthcare provider. ​

    ​DHMH continues to work with the Centers for Disease Control and Prevention (CDC), the United States Food and Drug Administration (FDA), and other states on the response to this outbreak.

    ###

    Stay connected: www.twitter.com/MarylandDHMH or www.facebook.com/MarylandDHMH

     

     

    ​